No Data
Immix Biopharma(IMMX.US) Officer Buys US$9,659.95 in Common Stock
$Immix Biopharma(IMMX.US)$ Officer Rachman Ilya M purchased 4,300 shares of common stock on May 14, 2024 at an average price of $2.2465 for a total value of $9,659.95.Source: Announcement What is stat
Immix Biopharma(IMMX.US) Officer Buys US$10,041.75 in Common Stock
$Immix Biopharma(IMMX.US)$ Officer Morris Gabriel S purchased 4,500 shares of common stock on May 14, 2024 at an average price of $2.2315 for a total value of $10,041.75.Source: Announcement What is s
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of
Immix Biopharma | 10-Q: Quarterly report
Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment
Immix Biopharma (IMMX) said Monday that the European Commission has granted orphan drug designation to NXC-201 for the treatment of multiple myeloma. The designation qualifies NXC-201 among others for
Express News | Immix Biopharma Awarded European Union Orphan Drug Designation for Nxc-201 in Multiple Myeloma